The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
Korean Journal of Urological Oncology
; : 48-59, 2019.
Article
Dans Ko
| WPRIM
| ID: wpr-760325
Responsable en Bibliothèque :
WPRO
ABSTRACT
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Prostate
/
Tumeurs de la prostate
/
Qualité de vie
/
Traitement médicamenteux
/
Corée
/
Oncologie médicale
Type d'étude:
Guideline
Limites du sujet:
Humans
Pays comme sujet:
Asia
langue:
Ko
Texte intégral:
Korean Journal of Urological Oncology
Année:
2019
Type:
Article